Wiley, Angewandte Chemie International Edition, 38(52), p. 10006-10009, 2013
Wiley, Angewandte Chemie, 38(125), p. 10190-10193, 2013
Full text: Download
Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.